Clinical trial of colon cancer diagnostic reagent by blood mRNA examination for practical use

Not Applicable

• Conditions: colon cancer

• Registration Number: JPRN-UMIN000018914
• Lead Sponsor: Kanazawa University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2015-09-04
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

Not provided

Exclusion Criteria

The patients who meet any of the criteria below will be excluded. 1) Patients who have been diagnosed with malignancy within 5 year of the date of the informed consent. 2) Patients who have been treated with interferon treatment within one year of the date of the informed consent, or is currently undergoing interferon treatment. 3) Patients who have been treated with adrenal hormone (except for local treatment) or biological drug (etc. infliximab) within 6 months. 4) Patients who have been treated with anti-cancer drug within 6 months of the informred consent. 5) Patients who are infected with hepatitis B, hepatitis C or other infectious diseases. 6) Patients who have been diagnosed with irritable bowel syndrome, ulcerative colitis, and Crohn disease. 7)Patients, who are judged to be not appropriate for entry by the trial responsible (collaborative) doctor

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
sensitivity, specificity

Secondary Outcome Measures

Name	Time	Method
positive predictive value and negative predictive value of stool occult blood test. positive predictive value and negative predictive value of blood mRNA test.